Is Dr Agarwal's Eye overvalued or undervalued?

As of 25 August 2025, Dr Agarwal's Eye has moved from a fair valuation to an expensive one. The company is currently considered overvalued based on its high valuation ratios, including a PE ratio of 43.29, a Price to Book Value of 11.94, and an EV to EBITDA of 22.62. These figures suggest that the stock is trading at a premium compared to its earnings and book value.
In comparison to its peers, Dr Agarwal's Eye's PE ratio is significantly lower than that of Max Healthcare, which stands at 98.51, indicating that while Dr Agarwal's is expensive, it is not the most overvalued in the sector. Apollo Hospitals, which is rated attractive, has a PE ratio of 71.67, further emphasizing the high valuation of Dr Agarwal's Eye. Despite a strong historical performance, including a remarkable 565.43% return over three years, the current valuation metrics suggest that the stock may not justify its price in the current market environment.